78 related articles for article (PubMed ID: 24222150)
21. International consensus on severe lung cancer-the first edition.
Zhou C; Li S; Liu J; Chu Q; Miao L; Cai L; Cai X; Chen Y; Cui F; Dong Y; Dong W; Fang W; He Y; Li W; Li M; Liang W; Lin G; Lin J; Lin X; Liu H; Liu M; Mu X; Hu Y; Hu J; Jin Y; Li Z; Qin Y; Ren S; Sun G; Shen Y; Su C; Tang K; Wu L; Wang M; Wang H; Wang K; Wang Y; Wang P; Wang H; Wang Q; Wang Z; Xie X; Xie Z; Xu X; Xu F; Yang M; Yang B; Yi X; Ye X; Ye F; Yu Z; Yue D; Zhang B; Zhang J; Zhang J; Zhang X; Zhang W; Zhao W; Zhu B; Zhu Z; Zhong W; Bai C; Chen L; Han B; Hu C; Lu S; Li W; Song Y; Wang J; Zhou C; Zhou J; Zhou Y; Saito Y; Ichiki Y; Igai H; Watanabe S; Bravaccini S; Fiorelli A; Petrella F; Nakada T; Solli P; Tsoukalas N; Kataoka Y; Goto T; Berardi R; He J; Zhong N
Transl Lung Cancer Res; 2021 Jun; 10(6):2633-2666. PubMed ID: 34295668
[No Abstract] [Full Text] [Related]
22. Patient performance status and cancer immunotherapy efficacy: a meta-analysis.
Bersanelli M; Brighenti M; Buti S; Barni S; Petrelli F
Med Oncol; 2018 Aug; 35(10):132. PubMed ID: 30128793
[TBL] [Abstract][Full Text] [Related]
23. G Protein-Coupled Receptor Signaling in Stem Cells and Cancer.
Lynch JR; Wang JY
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187360
[TBL] [Abstract][Full Text] [Related]
24. Phase II Clinical Trial of Gefitinib for the Treatment of Chemonaïve Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status.
Karim NA; Musaad S; Zarzour A; Patil S; Jazieh AR
Clin Med Insights Oncol; 2014; 8():121-8. PubMed ID: 25520566
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.
Koyama N; Uchida Y
Anticancer Res; 2013 Nov; 33(11):5083-9. PubMed ID: 24222153
[TBL] [Abstract][Full Text] [Related]
26. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
27. Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene.
Krawczyk P; Kowalski DM; Krawczyk KW; Szczyrek M; Mlak R; Rolski A; Szudy A; Kieszko R; Winiarczyk K; Milanowski J; Krzakowski M
Oncol Rep; 2013 Sep; 30(3):1463-72. PubMed ID: 23783797
[TBL] [Abstract][Full Text] [Related]
28. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
Maemondo M; Minegishi Y; Inoue A; Kobayashi K; Harada M; Okinaga S; Morikawa N; Oizumi S; Tanaka T; Isobe H; Kudoh S; Hagiwara K; Nukiwa T; Gemma A
J Thorac Oncol; 2012 Sep; 7(9):1417-22. PubMed ID: 22895139
[TBL] [Abstract][Full Text] [Related]
29. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
Okuma Y; Hosomi Y; Nagamata M; Yamada Y; Sekihara K; Kato K; Hishima T; Okamura T
Anticancer Res; 2013 Nov; 33(11):5057-64. PubMed ID: 24222150
[TBL] [Abstract][Full Text] [Related]
31. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
[TBL] [Abstract][Full Text] [Related]
32. EGFR mutations and clinical outcomes of chemotherapy for advanced non-small cell lung cancer: a meta-analysis.
Zhang Q; Dai HH; Dong HY; Sun CT; Yang Z; Han JQ
Lung Cancer; 2014 Sep; 85(3):339-45. PubMed ID: 25043903
[TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer.
Riedel RF; Febbo PG
Future Oncol; 2005 Aug; 1(4):461-6. PubMed ID: 16556022
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
